{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37426262", "DateRevised": {"Year": "2023", "Month": "07", "Day": "18"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "06", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1021/acsomega.3c00133"], "Journal": {"ISSN": "2470-1343", "JournalIssue": {"Volume": "8", "Issue": "26", "PubDate": {"Year": "2023", "Month": "Jul", "Day": "04"}}, "Title": "ACS omega", "ISOAbbreviation": "ACS Omega"}, "ArticleTitle": "Novel Pyrano[3,2-<i>c</i>]quinoline-1,2,3-triazole Hybrids as Potential Anti-Diabetic Agents: <i>In Vitro</i> \u03b1-Glucosidase Inhibition, Kinetic, and Molecular Dynamics Simulation.", "Pagination": {"StartPage": "23412", "EndPage": "23424", "MedlinePgn": "23412-23424"}, "Abstract": {"AbstractText": ["In this study, a novel series of pyrano[3,2-<i>c</i>]quinoline-1,2,3-triazole hybrids <b>8a-o</b> were synthesized and evaluated against the \u03b1-glucosidase enzyme. All compounds showed significant in vitro inhibitory activity (IC<sub>50</sub> values of 1.19 \u00b1 0.05 to 20.01 \u00b1 0.02 \u03bcM) compared to the standard drug acarbose (IC<sub>50</sub> = 750.0 \u03bcM). Among them, 2-amino-4-(3-((1-benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)phenyl)-5-oxo-5,6-dihydro-4<i>H</i>-pyrano[3,2-<i>c</i>]quinoline-3-carbonitrile (compound <b>8k</b>) demonstrated the best inhibitory effect toward \u03b1-glucosidase (IC<sub>50</sub> = 1.19 \u00b1 0.05 \u03bcM) with a competitive pattern of inhibition. Since compound <b>8k</b> was synthesized as a racemic mixture, molecular docking and dynamics simulations were performed on <i>R</i>- and <i>S</i>-enantiomers of compound <b>8k</b>. Based on the molecular docking results, both <i>R</i>- and <i>S</i>-enantiomers of compound <b>8k</b> displayed significant interactions with key residues including catalytic triad (Asp214, Glu276, and Asp349) in the enzyme active site. However, an in silico study indicated that <i>S</i>- and <i>R</i>-enantiomers were inversely located in the enzyme active site. The <i>R</i>-enantiomer formed a more stable complex with a higher binding affinity to the active site of \u03b1-glucosidase than that of the <i>S</i>- enantiomer. The benzyl ring in the most stable complex ((<i>R</i>)-compound <b>8k</b>) was located in the bottom of the binding site and interacted with the enzyme active site, while the pyrano[3,2-<i>c</i>]quinoline moiety occupied the high solvent accessible entrance of the active site. Thus, the synthesized pyrano[3,2-<i>c</i>]quinoline-1,2,3-triazole hybrids seem to be promising scaffolds for the development of novel \u03b1-glucosidase inhibitors."], "CopyrightInformation": "\u00a9 2023 The Authors. Published by American Chemical Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838683, Iran."}], "LastName": "Esmaili", "ForeName": "Soheila", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan 6517838678, Iran."}], "LastName": "Ebadi", "ForeName": "Ahmad", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan 6517838683, Iran."}], "LastName": "Khazaei", "ForeName": "Ardeshir", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan 6517838678, Iran."}], "LastName": "Ghorbani", "ForeName": "Hamideh", "Initials": "H"}, {"Identifier": ["0000-0002-8822-453X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}], "LastName": "Faramarzi", "ForeName": "Mohammad Ali", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran 1417614411, Iran."}], "LastName": "Mojtabavi", "ForeName": "Somayeh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran 1416753955, Iran."}], "LastName": "Mahdavi", "ForeName": "Mohammad", "Initials": "M"}, {"Identifier": ["0000-0001-8189-1586"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan 6517838678, Iran."}], "LastName": "Najafi", "ForeName": "Zahra", "Initials": "Z"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "ACS Omega", "NlmUniqueID": "101691658", "ISSNLinking": "2470-1343"}, "CoiStatement": "The authors declare no competing financial interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Deng Y.; Li N.; Wu Y.; Wang M.; Yang S.; Zheng Y.; Deng X.; Xiang D.; Zhu Y.; Xu P.; Zhai Z.; Zhang D.; Dai Z.; Gao J. Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019. Front. Endocrinol. 2021, 12, 672350.10.3389/fendo.2021.672350.", "ArticleIdList": ["10.3389/fendo.2021.672350", "PMC8281340", "34276558"]}, {"Citation": "Le\u00f3n-Jim\u00e9nez D.; Miramontes-Gonz\u00e1lez J. P.; M\u00e1rquez-L\u00f3pez L.; Astudillo-Mart\u00edn F.; Beltr\u00e1n-Romero L. M.; Moreno-Obreg\u00f3n F.; Escalada-San Mart\u00edn J. Basal insulin analogues in people with diabetes and chronic kidney disease. Diabetic Med. 2022, 39, e1467910.1111/dme.14679.", "ArticleIdList": ["10.1111/dme.14679", "34449911"]}, {"Citation": "Andreadi A.; Bellia A.; Di Daniele N.; Meloni M.; Lauro R.; Della-Morte D.; Lauro D. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases. Curr. Opin. Pharmacol. 2022, 62, 85\u201396. 10.1016/j.coph.2021.11.010.", "ArticleIdList": ["10.1016/j.coph.2021.11.010", "34959126"]}, {"Citation": "Bradley P. Hypothesis: Enhanced glucose availability and insulin resistance enhances an activated immune system and accounts for the obesity paradox. Clin. Obes. 2022, 12, e1252110.1111/cob.12521.", "ArticleIdList": ["10.1111/cob.12521", "35412022"]}, {"Citation": "Fadem S. Z.Staying Healthy with Kidney Disease; Springer, 2022."}, {"Citation": "Lin C.-F.; Liu H.-C.; Lin S.-Y. Kidney Function and Risk of Physical and Cognitive Impairment in Older Persons with Type 2 Diabetes at an Outpatient Clinic with Geriatric Assessment Implementation. Diabetes, Metab. Syndr. Obes.: Targets Ther. 2022, 15, 79\u201391. 10.2147/dmso.s341935.", "ArticleIdList": ["10.2147/dmso.s341935", "PMC8759987", "35046679"]}, {"Citation": "Escand\u00f3n-Rivera S.; Gonz\u00e1lez-Andrade M.; Bye R.; Linares E.; Navarrete A. s.; Mata R. \u03b1-Glucosidase Inhibitors from Brickellia cavanillesii. J. Nat. Prod. 2012, 75, 968\u2013974. 10.1021/np300204p.", "ArticleIdList": ["10.1021/np300204p", "22587572"]}, {"Citation": "Shen X.; Saburi W.; Gai Z.; Kato K.; Ojima-Kato T.; Yu J.; Komoda K.; Kido Y.; Matsui H.; Mori H.; et al. Structural analysis of the \u03b1-glucosidase HaG provides new insights into substrate specificity and catalytic mechanism. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2015, 71, 1382\u20131391. 10.1107/s139900471500721x.", "ArticleIdList": ["10.1107/s139900471500721x", "26057678"]}, {"Citation": "Hossain U.; Das A. K.; Ghosh S.; Sil P. C. An overview on the role of bioactive \u03b1-glucosidase inhibitors in ameliorating diabetic complications. Food Chem. Toxicol. 2020, 145, 111738.10.1016/j.fct.2020.111738.", "ArticleIdList": ["10.1016/j.fct.2020.111738", "PMC7480666", "32916220"]}, {"Citation": "Leonhardt W.; Hanefeld M.; Fischer S.; Schulze J. Efficacy of \u03b1-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur. J. Clin. Invest. 1994, 24, 45\u201349. 10.1111/j.1365-2362.1994.tb02256.x.", "ArticleIdList": ["10.1111/j.1365-2362.1994.tb02256.x", "8001628"]}, {"Citation": "Chapel C.; Garcia C.; Roingeard P.; Zitzmann N.; Dubuisson J.; Dwek R. A.; Trepo C.; Zoulim F.; Durantel D. Antiviral effect of \u03b1-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J. Gen. Virol. 2006, 87, 861\u2013871. 10.1099/vir.0.81503-0.", "ArticleIdList": ["10.1099/vir.0.81503-0", "16528036"]}, {"Citation": "Tundis R.; Loizzo M.; Menichini F. Natural products as \u03b1-amylase and \u03b1-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini-Rev. Med. Chem. 2010, 10, 315\u2013331. 10.2174/138955710791331007.", "ArticleIdList": ["10.2174/138955710791331007", "20470247"]}, {"Citation": "Mahmood N. A review of \u03b1-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes. Comp. Clin. Pathol. 2016, 25, 1253\u20131264. 10.1007/s00580-014-1967-x.", "ArticleIdList": ["10.1007/s00580-014-1967-x"]}, {"Citation": "Najafi Z.; Mahdavi M.; Saeedi M.; Karimpour-Razkenari E.; Asatouri R.; Vafadarnejad F.; Moghadam F. H.; Khanavi M.; Sharifzadeh M.; Akbarzadeh T. Novel tacrine-1, 2, 3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors. Eur. J. Med. Chem. 2017, 125, 1200\u20131212. 10.1016/j.ejmech.2016.11.008.", "ArticleIdList": ["10.1016/j.ejmech.2016.11.008", "27863370"]}, {"Citation": "Najafi Z.; Mahdavi M.; Saeedi M.; Karimpour-Razkenari E.; Edraki N.; Sharifzadeh M.; Khanavi M.; Akbarzadeh T. Novel tacrine-coumarin hybrids linked to 1, 2, 3-triazole as anti-Alzheimer\u2019s compounds: In vitro and in vivo biological evaluation and docking study. Bioorg. Chem. 2019, 83, 303\u2013316. 10.1016/j.bioorg.2018.10.056.", "ArticleIdList": ["10.1016/j.bioorg.2018.10.056", "30396115"]}, {"Citation": "Karypidou K.; Ribone S. R.; Quevedo M. A.; Persoons L.; Pannecouque C.; Helsen C.; Claessens F.; Dehaen W. Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents. Bioorg. Med. Chem. Lett. 2018, 28, 3472\u20133476. 10.1016/j.bmcl.2018.09.019.", "ArticleIdList": ["10.1016/j.bmcl.2018.09.019", "PMC7127349", "30286952"]}, {"Citation": "Tian Y.; Liu Z.; Liu J.; Huang B.; Kang D.; Zhang H.; De Clercq E.; Daelemans D.; Pannecouque C.; Lee K.-H.; et al. Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1, 4-disubstituted 1, 2, 3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. Eur. J. Med. Chem. 2018, 151, 339\u2013350. 10.1016/j.ejmech.2018.03.059.", "ArticleIdList": ["10.1016/j.ejmech.2018.03.059", "PMC6001364", "29635166"]}, {"Citation": "Son Hai D.; Thi Thu Ha N.; Tien Tung D.; Thi Kim Giang N.; Thi Thu Huong N.; Huu Anh H.; Thi Kim Van H.; Ngoc Toan V.; Toan D. N.; Thanh N. D. Synthesis, biological evaluation and induced fit docking simulation study of d-glucose-conjugated 1 H-1, 2, 3-triazoles having 4 H-pyrano [2, 3-d] pyrimidine ring as potential agents against bacteria and fungi. New J. Chem. 2022, 46, 8303\u20138323. 10.1039/d1nj05330b.", "ArticleIdList": ["10.1039/d1nj05330b"]}, {"Citation": "Bangalore P. K.; Vagolu S. K.; Bollikanda R. K.; Veeragoni D. K.; Choudante P. C.; Misra S.; Sriram D.; Sridhar B.; Kantevari S. Usnic acid enaminone-coupled 1, 2, 3-triazoles as antibacterial and antitubercular agents. J. Nat. Prod. 2019, 83, 26\u201335. 10.1021/acs.jnatprod.9b00475.", "ArticleIdList": ["10.1021/acs.jnatprod.9b00475", "31858800"]}, {"Citation": "Srinivas Reddy M.; Swamy Thirukovela N.; Narsimha S.; Ravinder M.; Kumar Nukala S. Synthesis of fused 1, 2, 3-triazoles of Clioquinol via sequential CuAAC and CH arylation; in vitro anticancer activity, in silico DNA topoisomerase II inhibitory activity and ADMET. J. Mol. Struct. 2022, 1250, 131747.10.1016/j.molstruc.2021.131747.", "ArticleIdList": ["10.1016/j.molstruc.2021.131747"]}, {"Citation": "Singh H.; Singh J. V.; Gupta M. K.; Saxena A. K.; Sharma S.; Nepali K.; Bedi P. M. S. Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Bioorg. Med. Chem. Lett. 2017, 27, 3974\u20133979. 10.1016/j.bmcl.2017.07.069.", "ArticleIdList": ["10.1016/j.bmcl.2017.07.069", "28797799"]}, {"Citation": "Singh H.; Kumar M.; Nepali K.; Gupta M. K.; Saxena A. K.; Sharma S.; Bedi P. M. S. Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Eur. J. Med. Chem. 2016, 116, 102\u2013115. 10.1016/j.ejmech.2016.03.050.", "ArticleIdList": ["10.1016/j.ejmech.2016.03.050", "27060762"]}, {"Citation": "Sharma S.; Gupta M. K.; Saxena A. K.; Bedi P. M. S. Triazole linked mono carbonyl curcumin-isatin bifunctional hybrids as novel anti tubulin agents: Design, synthesis, biological evaluation and molecular modeling studies. Bioorg. Med. Chem. 2015, 23, 7165\u20137180. 10.1016/j.bmc.2015.10.013.", "ArticleIdList": ["10.1016/j.bmc.2015.10.013", "26515041"]}, {"Citation": "Singh J.; Sharma S.; Saxena A. K.; Nepali K.; Bedi P. M. S. Synthesis of 1, 2, 3-triazole tethered bifunctional hybrids by click chemistry and their cytotoxic studies. Med. Chem. Res. 2013, 22, 3160\u20133169. 10.1007/s00044-012-0312-7.", "ArticleIdList": ["10.1007/s00044-012-0312-7"]}, {"Citation": "Wang G.; Peng Z.; Wang J.; Li X.; Li J. Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential \u03b1-glucosidase inhibitors. Eur. J. Med. Chem. 2017, 125, 423\u2013429. 10.1016/j.ejmech.2016.09.067.", "ArticleIdList": ["10.1016/j.ejmech.2016.09.067", "27689725"]}, {"Citation": "Avula S. K.; Khan A.; Rehman N. U.; Anwar M. U.; Al-Abri Z.; Wadood A.; Riaz M.; Csuk R.; Al-Harrasi A. Synthesis of 1H-1,2,3-triazole derivatives as new \u03b1-glucosidase inhibitors and their molecular docking studies. Bioorg. Chem. 2018, 81, 98\u2013106. 10.1016/j.bioorg.2018.08.008.", "ArticleIdList": ["10.1016/j.bioorg.2018.08.008", "30118991"]}, {"Citation": "Asgari M. S.; Mohammadi-Khanaposhtani M.; Kiani M.; Ranjbar P. R.; Zabihi E.; Pourbagher R.; Rahimi R.; Faramarzi M. A.; Biglar M.; Larijani B.; et al. Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro \u03b1-glucosidase inhibition, kinetic, and docking studies. Bioorg. Chem. 2019, 92, 103206.10.1016/j.bioorg.2019.103206.", "ArticleIdList": ["10.1016/j.bioorg.2019.103206", "31445191"]}, {"Citation": "Mohammadi-Khanaposhtani M.; Rezaei S.; Khalifeh R.; Imanparast S.; Faramarzi M. A.; Bahadorikhalili S.; Safavi M.; Bandarian F.; Nasli Esfahani E.; Mahdavi M.; et al. Design, synthesis, docking study, \u03b1-glucosidase inhibition, and cytotoxic activities of acridine linked to thioacetamides as novel agents in treatment of type 2 diabetes. Bioorg. Chem. 2018, 80, 288\u2013295. 10.1016/j.bioorg.2018.06.035.", "ArticleIdList": ["10.1016/j.bioorg.2018.06.035", "29980114"]}, {"Citation": "Taha M.; Ismail N. H.; Imran S.; Wadood A.; Rahim F.; Ali M.; Rehman A. U. Novel quinoline derivatives as potent in vitro \u03b1-glucosidase inhibitors: in silico studies and SAR predictions. MedChemComm 2015, 6, 1826\u20131836. 10.1039/c5md00280j.", "ArticleIdList": ["10.1039/c5md00280j"]}, {"Citation": "Lee H.-W.; Yang J.-Y.; Lee H.-S. Quinoline-2-carboxylic acid isolated from Ephedra pachyclada and its structural derivatives show inhibitory effects against \u03b1-glucosidase and \u03b1-amylase. J. Korean Soc. Appl. Biol. Chem. 2014, 57, 441\u2013444. 10.1007/s13765-014-4156-3.", "ArticleIdList": ["10.1007/s13765-014-4156-3"]}, {"Citation": "Chehardoli G.; Gholamhoseini P.; Ebadi A.; Ziaei M.; Akbarzadeh T.; Saeedi M.; Mahdavi M.; Khoshneviszadeh M.; Najafi Z. 6-Methoxy-1-tetralone Derivatives Bearing an N-Arylpyridinium Moiety as Cholinesterase Inhibitors: Design, Synthesis, Biological Evaluation, and Molecular Docking Study. ChemistrySelect 2022, 7, e20220197710.1002/slct.202201977.", "ArticleIdList": ["10.1002/slct.202201977"]}, {"Citation": "Sadafi Kohnehshahri M.; Chehardoli G.; Bahiraei M.; Akbarzadeh T.; Ranjbar A.; Rastegari A.; Najafi Z. Novel tacrine-based acetylcholinesterase inhibitors as potential agents for the treatment of Alzheimer\u2019s disease: Quinolotacrine hybrids. Mol. Diversity 2022, 26, 489\u2013503. 10.1007/s11030-021-10307-2.", "ArticleIdList": ["10.1007/s11030-021-10307-2", "34491490"]}, {"Citation": "Liu M.; Zhang W.; Qiu L.; Lin X. Synthesis of butyl-isobutyl-phthalate and its interaction with -glucosidase in vitro. J. Biochem. 2011, 149, 27\u201333. 10.1093/jb/mvq110.", "ArticleIdList": ["10.1093/jb/mvq110", "20870646"]}, {"Citation": "Altschul S. F.; Gish W.; Miller W.; Myers E. W.; Lipman D. J. Basic local alignment search tool. J. Mol. Biol. 1990, 215, 403\u2013410. 10.1016/s0022-2836(05)80360-2.", "ArticleIdList": ["10.1016/s0022-2836(05)80360-2", "2231712"]}, {"Citation": "Somakala K.; Amir M.; Sharma V.; Wakode S. Synthesis and pharmacological evaluation of pyrazole derivatives containing sulfonamide moiety. Monatsh. fur Chem. 2016, 147, 2017\u20132029. 10.1007/s00706-016-1694-x.", "ArticleIdList": ["10.1007/s00706-016-1694-x"]}, {"Citation": "Lei M.; Ma L.; Hu L. A green, efficient, and rapid procedure for the synthesis of 2-amino-3-cyano-1, 4, 5, 6-tetrahydropyrano [3, 2-c] quinolin-5-one derivatives catalyzed by ammonium acetate. Tetrahedron Lett. 2011, 52, 2597\u20132600. 10.1016/j.tetlet.2011.03.061.", "ArticleIdList": ["10.1016/j.tetlet.2011.03.061"]}, {"Citation": "Adib M.; Peytam F.; Rahmanian-Jazi M.; Mahernia S.; Bijanzadeh H. R.; Jahani M.; Mohammadi-Khanaposhtani M.; Imanparast S.; Faramarzi M. A.; Mahdavi M.; et al. New 6-amino-pyrido[2,3-d]pyrimidine-2,4-diones as novel agents to treat type 2 diabetes: A simple and efficient synthesis, \u03b1-glucosidase inhibition, molecular modeling and kinetic study. Eur. J. Med. Chem. 2018, 155, 353\u2013363. 10.1016/j.ejmech.2018.05.046.", "ArticleIdList": ["10.1016/j.ejmech.2018.05.046", "29902721"]}, {"Citation": "Thompson J. D.; Higgins D. G.; Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673\u20134680. 10.1093/nar/22.22.4673.", "ArticleIdList": ["10.1093/nar/22.22.4673", "PMC308517", "7984417"]}, {"Citation": "\u0160ali A.; Blundell T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234, 779\u2013815. 10.1006/jmbi.1993.1626.", "ArticleIdList": ["10.1006/jmbi.1993.1626", "8254673"]}, {"Citation": "Laskowski R. A.; MacArthur M. W.; Moss D. S.; Thornton J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283\u2013291. 10.1107/s0021889892009944.", "ArticleIdList": ["10.1107/s0021889892009944"]}, {"Citation": "Neese F.; Wennmohs F.; Becker U.; Riplinger C. The ORCA quantum chemistry program package. J. Chem. Phys. 2020, 152, 224108.10.1063/5.0004608.", "ArticleIdList": ["10.1063/5.0004608", "32534543"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "1", "Day": "8"}, {"Year": "2023", "Month": "5", "Day": "30"}, {"Year": "2023", "Month": "7", "Day": "10", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "7", "Day": "10", "Hour": "6", "Minute": "42"}, {"Year": "2023", "Month": "7", "Day": "10", "Hour": "5", "Minute": "7"}, {"Year": "2023", "Month": "6", "Day": "20"}], "PublicationStatus": "epublish", "ArticleIdList": ["37426262", "PMC10324058", "10.1021/acsomega.3c00133"]}}], "PubmedBookArticle": []}